查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1279852

2023-2030年全球软组织肉瘤市场规模研究与预测，按治疗方法、给药途径、终端用户和区域分析。

Global Soft Tissue Sarcoma Market Size study & Forecast, by Treatment, By Route of Administration, By End-users, and Regional Analysis, 2023-2030
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3个工作天内

价格

软组织肉瘤是一种起源于身体软组织的癌症，如肌肉、肌腱、脂肪、神经、血管和结缔组织。身体软组织中的肿块或肿胀是软组织肉瘤的一个迹象。身体上有许多不同的位置会发生软组织肉瘤，这要通过活检来确定。全球市场的增长是由以下因素驱动的，如新型疗法的不断采用，对个性化医疗的日益关注，人口的不断增加，以及医疗支出的增加，再加上有利的报销政策。

此外，癌症发病率的激增正成为全球市场增长的一个催化因素。根据世界卫生组织的数据，2020年，估计全球约有1930万个新的癌症病例，预计到2040年将会增加并可能达到3030万个病例。因此，上述这些因素正在推动软组织肉瘤市场在估计期内的增长。此外，诊断和治疗方案的不断进步，以及对研究和开发的投资不断增加，在预测的几年里呈现出各种有利可图的机会。然而，治疗的高成本和软组织肉瘤药物的副作用正在阻碍整个2023-2030年预测期的市场增长。

全球软组织肉瘤市场研究考虑的主要地区包括亚太、北美、欧洲、拉美和中东及非洲。由于对靶向治疗的需求激增，对个性化医疗的关注度上升，以及存在完善的医疗设施，北美在2022年主导了市场。而亚太地区在预测期内预计将以最高的复合年增长率增长，原因是软组织肉瘤的发病率上升，医疗支出增加，以及对研究和开发的投资增加等因素。

该研究的目的是确定近年来不同领域和国家的市场规模，并对未来几年的价值进行预测。该报告旨在将研究涉及的国家内的行业的定性和定量方面都纳入其中。

该报告还提供了关于关键方面的详细信息，如驱动因素和挑战，这将确定市场的未来增长。此外，它还纳入了微观市场的潜在机会，供利益相关者投资，并详细分析了竞争格局和主要参与者的产品。.

目录

第一章：执行摘要

  • 市场简介
  • 2020-2030年全球和细分市场的估计和预测
    • 2020-2030年软组织肉瘤市场，按地区划分
    • 2020-2030年软组织肉瘤市场，按治疗方法划分
    • 2020-2030年软组织肉瘤市场，按给药途径划分
    • 2020-2030年软组织肉瘤市场，按终端用户划分
  • 主要趋势
  • 估算方法
  • 研究假设

第二章：全球软组织肉瘤市场的定义和范围

  • 本研究的目的
  • 市场定义和范围
    • 行业演变
    • 研究的范围
  • 研究考虑的年份
  • 货币兑换率

第三章：全球软组织肉瘤市场动态

  • 软组织肉瘤市场影响分析(2020-2030)
    • 市场驱动力
      • 新型疗法的采用不断增加
      • 癌症发病率的激增
    • 市场挑战
      • 治疗费用高
      • 软组织肉瘤药物的副作用
    • 市场机会
      • 诊断法和治疗方案的不断进步
      • 研究和开发方面的投资不断增加

第四章：全球软组织肉瘤市场行业分析

  • 波特五力模型
    • 供应商的议价能力
    • 买方的讨价还价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争性的竞争
  • 波特五力影响分析
  • PEST分析
    • 政治
    • 经济
    • 社会
    • 技术
    • 环境
    • 法律问题
  • 最佳投资机会
  • 最佳策略
  • COVID-19影响分析
  • 颠覆性趋势
  • 行业专家的观点
  • 分析师建议与结论

第五章：全球软组织肉瘤市场，按治疗方法划分

  • 市场简介
  • 全球软组织肉瘤市场，按治疗方法，性能-潜力分析
  • 2020-2030年全球软组织肉瘤市场按治疗方法的估计和预测
  • 软组织肉瘤市场，細項分析
    • 靶向治疗
    • 化疗
    • 抗血管生成药物
    • 放射治疗

第六章：全球软组织肉瘤市场，按给药途径划分

  • 市场简介
  • 按给药途径分類的全球软组织肉瘤市场，表现 - 潜力分析
  • 2020-2030年全球软组织肉瘤市场按给药途径的估计和预测
  • 软组织肉瘤市场，分项分析
    • 口服
    • 肠外
    • 其他途径

第7章 ：全球软组织肉瘤市场，按终端用户划分

  • 市场简介
  • 按终端用户分類的全球软组织肉瘤市场，表现 - 潜力分析
  • 2020-2030年全球软组织肉瘤市场按终端用户估计和预测的情况
  • 软组织肉瘤市场，次级細項分析
    • 医院
    • 家庭护理
    • 专科中心
    • 其他

第八章：全球软组织肉瘤市场，区域分析

  • 最领先的国家
  • 新兴国家
  • 软组织肉瘤市场，区域市场简介
  • 北美洲
    • 美国
      • 2020-2030年，治疗方法的细分估计和预测
      • 2020-2030年，给药途径的细分估计和预测
      • 2020-2030年终端用户分类估计和预测
    • 加拿大
  • 欧洲软组织肉瘤市场简介
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 意大利
    • 欧洲其他地区
  • 亚太地区软组织肉瘤市场简介
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 韩国
    • 亚太其他地区
  • 拉丁美洲软组织肉瘤市场简介
    • 巴西
    • 墨西哥
  • 中东和非洲
    • 沙特阿拉伯
    • 南非
    • 中东和非洲其他地区

第九章：竞争情报

  • 主要公司SWOT分析
    • 公司1
    • 公司二
    • 公司3
  • 顶级市场战略
  • 公司简介
    • F. Hoffmann-La Roche Ltd. (Switzerland)
      • 关键信息
      • 概况
      • 财务（取决于数据的可用性）
      • 产品摘要
      • 近期发展情况
    • Mylan N.V. (U.S.)
    • Teva Pharmaceutical Industries Ltd. (Israel)
    • Sanofi (France)
    • Pfizer Inc. (U.S.)
    • GSK plc (U.K.)
    • Novartis AG (Switzerland)
    • Bayer AG (Germany)
    • Merck & Co., Inc. (U.S.)
    • Sun Pharmaceutical Industries Ltd. (India)

第十章 ：研究过程

  • 研究过程
    • 资料探勘
    • 数据分析
    • 市场评估
    • 验证
    • 出版
  • 研究属性
  • 研究假设

Global Soft Tissue Sarcoma Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Soft tissue sarcoma is a type of cancer that originates in the soft tissues of the body, such as muscles, tendons, fat, nerves, blood vessels, and connective tissues. A lump or swelling in a body's soft tissue is an indication of soft tissue sarcoma. There are many different locations on the body where soft tissue sarcomas develop, which is identified through biopsy. The global market growth is driven by factors such as the rising adoption of novel therapies, growing focus on personalized medicine, escalating population, and increasing healthcare expenditure, coupled with favorable reimbursement policies.

In addition, the surge in the incidences of cancer is acting as a catalyzing factor for market growth across the globe. According to the World Health Organization, in 2020, it was estimated that around 19.3 million new cancer cases were recorded globally, which is projected to increase and likely to reach 30.3 million cases by the year 2040. Thus, these aforementioned factors are propelling the growth of the soft tissue sarcoma market during the estimated period. Moreover, the rising advancements in diagnostics and treatment options, as well as increasing investments in research and development is presenting various lucrative opportunities over the forecasting years. However, the high cost of treatments and the side effects of soft tissue sarcoma drugs are hampering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Soft Tissue Sarcoma Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the surging demand for targeted therapies, rising focus on personalized medicine, and the presence of well-established healthcare facilities. Whereas, Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the rising prevalence of soft tissue sarcoma, increasing healthcare expenditure, and growing investments in research and development.

Major market players included in this report are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GSK plc (U.K.)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Merck & Co., Inc. (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)

Recent Developments in the Market:

  • In 2019, Pfizer announced that Vitrakvi (larotrectinib) had received European Commission approval for the treatment of advanced soft tissue sarcoma. Vitrakvi - a targeted medication is available to patients whose tumours have a particular genetic mutation.
  • In 2019, Johnson & Johnson declared that the US Food and Drug Administration had authorized JNJ-4528 as a medication for the management of relapsed or refractory multiple myeloma. JNJ-4528 is a CAR-T cell therapy that is developed for use in the treatment of several malignancies, including some types of sarcomas.

Global Soft Tissue Sarcoma Market Report Scope:

  • Historical Data: - 2020 - 2021
  • Base Year for Estimation: - 2022
  • Forecast period: - 2023-2030
  • Report Coverage: - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: - Treatment, Route of Administration, End-users, Region
  • Regional Scope: - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Treatment:

  • Targeted Therapy
  • Chemotherapy
  • Anti-Angiogenesis Drugs
  • Radiation Therapy

By Route of Administration:

  • Oral
  • Parenteral
  • Others

By End-users:

  • Hospitals
  • Homecare
  • Speciality Centres
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Soft Tissue Sarcoma Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Soft Tissue Sarcoma Market, by Treatment, 2020-2030 (USD Billion)
    • 1.2.3. Soft Tissue Sarcoma Market, by Route of Administration, 2020-2030 (USD Billion)
    • 1.2.4. Soft Tissue Sarcoma Market, by End-users, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Soft Tissue Sarcoma Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Soft Tissue Sarcoma Market Dynamics

  • 3.1. Soft Tissue Sarcoma Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising adoption of novel therapies
      • 3.1.1.2. Surge in the incidences of cancer
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost of treatments
      • 3.1.2.2. Side effects of soft tissue sarcoma drugs
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising advancements in diagnostics and treatment options
      • 3.1.3.2. Increasing investments in research and development

Chapter 4. Global Soft Tissue Sarcoma Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Soft Tissue Sarcoma Market, by Treatment

  • 5.1. Market Snapshot
  • 5.2. Global Soft Tissue Sarcoma Market by Treatment, Performance - Potential Analysis
  • 5.3. Global Soft Tissue Sarcoma Market Estimates & Forecasts by Treatment 2020-2030 (USD Billion)
  • 5.4. Soft Tissue Sarcoma Market, Sub Segment Analysis
    • 5.4.1. Targeted Therapy
    • 5.4.2. Chemotherapy
    • 5.4.3. Anti-Angiogenesis Drugs
    • 5.4.4. Radiation Therapy

Chapter 6. Global Soft Tissue Sarcoma Market, by Route of Administration

  • 6.1. Market Snapshot
  • 6.2. Global Soft Tissue Sarcoma Market by Route of Administration, Performance - Potential Analysis
  • 6.3. Global Soft Tissue Sarcoma Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
  • 6.4. Soft Tissue Sarcoma Market, Sub Segment Analysis
    • 6.4.1. Oral
    • 6.4.2. Parenteral
    • 6.4.3. Others

Chapter 7. Global Soft Tissue Sarcoma Market, by End-users

  • 7.1. Market Snapshot
  • 7.2. Global Soft Tissue Sarcoma Market by End-users, Performance - Potential Analysis
  • 7.3. Global Soft Tissue Sarcoma Market Estimates & Forecasts by End-users 2020-2030 (USD Billion)
  • 7.4. Soft Tissue Sarcoma Market, Sub Segment Analysis
    • 7.4.1. Hospitals
    • 7.4.2. Homecare
    • 7.4.3. Speciality Centres
    • 7.4.4. Others

Chapter 8. Global Soft Tissue Sarcoma Market, Regional Analysis

  • 8.1. Top Leading Countries
  • 8.2. Top Emerging Countries
  • 8.3. Soft Tissue Sarcoma Market, Regional Market Snapshot
  • 8.4. North America Soft Tissue Sarcoma Market
    • 8.4.1. U.S. Soft Tissue Sarcoma Market
      • 8.4.1.1. Treatment breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2. Route of Administration breakdown estimates & forecasts, 2020-2030
      • 8.4.1.3. End-users breakdown estimates & forecasts, 2020-2030
    • 8.4.2. Canada Soft Tissue Sarcoma Market
  • 8.5. Europe Soft Tissue Sarcoma Market Snapshot
    • 8.5.1. U.K. Soft Tissue Sarcoma Market
    • 8.5.2. Germany Soft Tissue Sarcoma Market
    • 8.5.3. France Soft Tissue Sarcoma Market
    • 8.5.4. Spain Soft Tissue Sarcoma Market
    • 8.5.5. Italy Soft Tissue Sarcoma Market
    • 8.5.6. Rest of Europe Soft Tissue Sarcoma Market
  • 8.6. Asia-Pacific Soft Tissue Sarcoma Market Snapshot
    • 8.6.1. China Soft Tissue Sarcoma Market
    • 8.6.2. India Soft Tissue Sarcoma Market
    • 8.6.3. Japan Soft Tissue Sarcoma Market
    • 8.6.4. Australia Soft Tissue Sarcoma Market
    • 8.6.5. South Korea Soft Tissue Sarcoma Market
    • 8.6.6. Rest of Asia Pacific Soft Tissue Sarcoma Market
  • 8.7. Latin America Soft Tissue Sarcoma Market Snapshot
    • 8.7.1. Brazil Soft Tissue Sarcoma Market
    • 8.7.2. Mexico Soft Tissue Sarcoma Market
  • 8.8. Middle East & Africa Soft Tissue Sarcoma Market
    • 8.8.1. Saudi Arabia Soft Tissue Sarcoma Market
    • 8.8.2. South Africa Soft Tissue Sarcoma Market
    • 8.8.3. Rest of Middle East & Africa Soft Tissue Sarcoma Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Company 1
    • 9.1.2. Company 2
    • 9.1.3. Company 3
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. F. Hoffmann-La Roche Ltd. (Switzerland)
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Recent Developments
    • 9.3.2. Mylan N.V. (U.S.)
    • 9.3.3. Teva Pharmaceutical Industries Ltd. (Israel)
    • 9.3.4. Sanofi (France)
    • 9.3.5. Pfizer Inc. (U.S.)
    • 9.3.6. GSK plc (U.K.)
    • 9.3.7. Novartis AG (Switzerland)
    • 9.3.8. Bayer AG (Germany)
    • 9.3.9. Merck & Co., Inc. (U.S.)
    • 9.3.10. Sun Pharmaceutical Industries Ltd. (India)

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Soft Tissue Sarcoma Market, report scope
  • TABLE 2. Global Soft Tissue Sarcoma Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Soft Tissue Sarcoma Market estimates & forecasts by Treatment 2020-2030 (USD Billion)
  • TABLE 4. Global Soft Tissue Sarcoma Market estimates & forecasts by Route of Administration 2020-2030 (USD Billion)
  • TABLE 5. Global Soft Tissue Sarcoma Market estimates & forecasts by End-users 2020-2030 (USD Billion)
  • TABLE 6. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. U.S. Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17. U.S. Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18. U.S. Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. Canada Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 20. Canada Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. Canada Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. UK Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 23. UK Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. UK Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. Germany Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 26. Germany Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. Germany Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. France Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 29. France Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. France Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. Italy Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 32. Italy Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. Italy Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Spain Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 35. Spain Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. Spain Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. RoE Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 38. RoE Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. RoE Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. China Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 41. China Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. China Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. India Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 44. India Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. India Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. Japan Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 47. Japan Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. Japan Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. South Korea Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 50. South Korea Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. South Korea Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. Australia Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 53. Australia Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. Australia Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. RoAPAC Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. Brazil Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 59. Brazil Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. Brazil Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Mexico Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 62. Mexico Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. Mexico Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. RoLA Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 65. RoLA Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. RoLA Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. Saudi Arabia Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 68. South Africa Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. RoMEA Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70. List of secondary sources, used in the study of global Soft Tissue Sarcoma Market
  • TABLE 71. List of primary sources, used in the study of global Soft Tissue Sarcoma Market
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Soft Tissue Sarcoma Market, research methodology
  • FIG 2. Global Soft Tissue Sarcoma Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Soft Tissue Sarcoma Market, key trends 2022
  • FIG 5. Global Soft Tissue Sarcoma Market, growth prospects 2023-2030
  • FIG 6. Global Soft Tissue Sarcoma Market, porters 5 force model
  • FIG 7. Global Soft Tissue Sarcoma Market, pest analysis
  • FIG 8. Global Soft Tissue Sarcoma Market, value chain analysis
  • FIG 9. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Soft Tissue Sarcoma Market, regional snapshot 2020 & 2030
  • FIG 15. North America Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable